Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
SAB Biotherapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
SABS
Nasdaq
8731
https://www.sab.bio/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for SAB Biotherapeutics Inc
SAB Biotherapeutics Provides SAB-142 Trial Update
- Apr 16th, 2024 11:15 am
SAB Biotherapeutics to Present at INNODIA Annual Meeting
- Apr 8th, 2024 11:15 am
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
- Apr 4th, 2024 11:15 am
SAB Biotherapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
- Apr 1st, 2024 10:56 am
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
- Mar 29th, 2024 11:15 am
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
- Mar 25th, 2024 2:15 pm
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
- Feb 23rd, 2024 1:00 pm
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Feb 8th, 2024 1:00 pm
SAB Biotherapeutics Announces Executive Leadership Change
- Feb 2nd, 2024 12:30 pm
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Jan 23rd, 2024 10:58 pm
Individual investors are SAB Biotherapeutics, Inc.'s (NASDAQ:SABS) biggest owners and were rewarded after market cap rose by US$535m last week
- Jan 5th, 2024 10:37 am
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
- Jan 2nd, 2024 9:30 pm
SAB Biotherapeutics Starts Human Clinical Trial of Diabetes Treatment
- Nov 29th, 2023 6:29 pm
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
- Nov 29th, 2023 12:30 pm
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
- Nov 20th, 2023 12:30 pm
SAB Biotherapeutics 3Q Loss Narrows, Completes $67.1M in Financing
- Nov 14th, 2023 6:35 pm
SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes
- Nov 14th, 2023 12:30 pm
SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates
- Nov 14th, 2023 12:15 pm
SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference
- Nov 9th, 2023 12:30 pm
SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer
- Oct 24th, 2023 11:30 am
Scroll